



an Open Access Journal by MDPI

# **Polymeric Nanovaccines for Immune Modulation**

Guest Editors:

#### Dr. Saji Uthaman

Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA

#### Prof. Dr. In-Kyu Park

Department of Biomedical Sciences, Chonnam National University Medical School, 160 Baekseo-ro, Gwangju 58128, Korea

Deadline for manuscript submissions: closed (10 March 2022)

#### **Message from the Guest Editors**

Vaccination is one of the most effective ways to cure human diseases. With the advancements in science and technology, nanovaccines comprising nanoparticles that are either used as adjuvants or carriers has emerged as one of the most effective treatment strategies for health promotion and disease prevention. Nanovaccines are reported to be highly efficient in inducing humoral and cellmediated immune responses and demonstrate high antigen loading. enhanced immunogenicity. and controlled antigen presentation. Polymers from the natural or synthetic route are often used for developing nanovaccines which could be easily internalized by antigen-presenting cells and exert immune modulations owing to the unique physiochemical properties of nanoparticles.

We are calling for manuscripts detailing natural and synthetic polymeric nanovaccines, anticancer nanovaccine delivery systems, immune modulating polymeric nanoparticles, etc. We sincerely hope this Special Issue serves as a platform for the exchange of the latest developments in the field of polymeric nano vaccines.









an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## **Contact Us**

*Vaccines* Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/vaccines vaccines@mdpi.com X@Vaccines\_MDPI